Recent Announcements
PhotoPharmics Announces First Subject Completes FDA Pivotal Clinical Trial for the Celeste Device in Parkinson’s
PhotoPharmics, a leader in non-invasive phototherapy for neurological disorders, has reached a significant milestone in its ongoing FDA pivotal “Light for PD” trial for the Celeste therapeutic device. The first subject has successfully completed the full 6-month treatment course and clinical visits, marking an important step towards the successful completion of the trial and future FDA authorization of Celeste in treating Parkinson’s disease (PD).
PhotoPharmics Welcomes Three Renowned Experts to Its Clinical & Scientific Advisory Board
PhotoPharmics, an innovator in light-based therapies for neurodegenerative diseases, proudly announces the appointment of three eminent experts to its Clinical & Scientific Advisory Board (CSAB). The new members—Dr. Charles H. Adler, Dr. George Brainard, and Dr. Robert A. Hauser—bring unparalleled expertise to the advisory board, reinforcing PhotoPharmics’ mission to pioneer groundbreaking treatments for Parkinson’s disease and other neurodegenerative disorders.
PhotoPharmics Enrolls First 100 Participants in Groundbreaking Parkinson’s Disease Trial
PhotoPharmics, a leader in neurodegenerative disease phototherapy, today announced the enrollment of the first 100 subjects in its Light for PD clinical trial. This marks a significant milestone in evaluating Celeste, the company’s FDA Breakthrough light therapy device for Parkinson’s disease (PD). Organizers are on track to enroll 300 subjects—interested individuals with PD may find details at lightforpd.com.
The Light for PD trial is a randomized, double-blind, placebo-controlled study that aims to demonstrate safety and significant improvement in motor and non-motor symptoms beyond current medical care in PD. Parkinson’s disease happens when the brain can no longer regulate essential signaling for movement and other function. Recent discoveries implicate the eyes as part of this signaling process. Celeste passively delivers specific wavelengths of light aimed to restore retinal signaling, improving function and quality of life for those living with PD.
Featured Article
How Parkinson’s Affects Sleep and Vice-Versa
When most people think of Parkinson’s Disease (PD), the first symptom to come to mind are physical tremors and other movement symptoms. However, most people with Parkinson’s experience a wide range of non-motor symptoms that can often be more disruptive to their daily...
How Parkinson’s Affects Sleep and Vice-Versa
When most people think of Parkinson’s Disease (PD), the first symptom to come to mind are physical tremors and other movement symptoms. However, most people with Parkinson’s experience a wide range of non-motor symptoms that can often be more disruptive to their daily...
Archived Content